Wessex Haematology NETWORK

CHRONIC LYMPHOCYTIC LEUKAEMIA

First-line treatment: cardiovascular fit

Offer a clinical trial if available

iwCLL criteria met

17p/TP53 intact

- Mutated IGHV
- Unmutated IGHV

1ST CHOICE
Fixed duration

Venetoclax + obinutuzumab
or
Venetoclax + ibrutinib*

2ND CHOICE
Continuous

Acalabrutinib
or
Zanubritinib

Del17p / TP53 mutated

- Mutated IGHV
- Unmutated IGHV

1ST CHOICE
Continuous

Acalabrutinib
or
Zanubritinib

2ND CHOICE
Fixed duration

Venetoclax + obinutuzumab
or
Ibrutinib + venetoclax*

Check IGHV mutation status and TP53 (FISH and mutation) at diagnosis. Bone marrow not usually required unless cytopenias of unclear cause.

CV fit – absence of uncontrolled hypertension, arrhythmia or heart failure.

***** Caution in older patients with high CIRS score; sudden death and ventricular fibrillation seen in trials.

Authors: Dr David Dutton and Prof Francesco Forconi

CHRONIC LYMPHOCYTIC LEUKAEMIA

First-line treatment: cardiovascular unfit

Offer a clinical trial if available



Check IGHV mutation status and TP53 (FISH and mutation) at diagnosis.
Bone marrow not usually required unless cytopenias of unclear cause.

CV fit – absence of uncontrolled hypertension, arrhythmia or heart failure.

Authors: Dr David Dutton and Prof Francesco Forconi